# Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages

## TL;DR

This review explores CAR-macrophage immunotherapy as a new approach to treat solid tumors by leveraging macrophages' unique abilities.

## Contribution

The paper introduces CAR-macrophage therapies as a novel strategy to address limitations of CAR-T cells in solid tumors.

## Key findings

- CAR-macrophages have tumor-homing and phagocytic abilities that make them suitable for targeting solid tumors.
- The review highlights advances in CAR design and macrophage engineering for improved therapeutic outcomes.
- Challenges such as cell sourcing and durability remain, but innovative strategies are being explored to enhance efficacy.

## Abstract

Chimeric antigen receptor (CAR)-engineered immune cell therapies have revolutionized cancer treatment, with CAR-T cells demonstrating remarkable efficacy against hematological malignancies. However, the effectiveness of CAR-T and other lymphocyte-based therapies against solid tumors remains limited, primarily due to the immunosuppressive tumor microenvironment and poor infiltration of effector cells. Recently, CAR-macrophage (CAR-M) immunotherapy has emerged as a promising strategy to overcome these barriers. Leveraging the innate tumor-homing ability, phagocytic function, and antigen-presenting capacity of macrophages, CAR-M therapies offer unique advantages for targeting solid tumors. This review provides a comprehensive overview of the development and current state of CAR-Macrophage immunotherapy, including advances in CAR design and macrophage engineering, preclinical and clinical progress, and mechanistic insights into their anti-tumor activity. The review critically examined both the benefits and limitations of CAR-M approaches, addressing persistent challenges such as cell sourcing, durability, and safety, while also exploring innovative strategies to enhance therapeutic efficacy. Finally, future perspectives and the potential clinical impact of CAR-macrophage therapies were outlined, underscoring their emerging role in the evolving landscape of cancer immunotherapy.